MedTrace Logo

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 980

Last updated 2026-05-05

No results posted yet for this study

Summary

Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alone, and RIV and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the RIV alone, rC19 (dose 1) alone, and RIV + rC19 study groups to control for the number of injections and to maintain observer blinding. Thus, each participant will receive two injections at enrollment, one in each deltoid muscle.

Study details include:

* The study duration will be approximately 12 months
* Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on Day(D) 01
* Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose)
* The visit frequency for participants will be D01 and D30, and D09-D366 (telephone call)

Number of Participants:

Approximately 980 participants are expected to be randomized.

Conditions

  • COVID-19 Immunization
  • Influenza Immunization

Interventions

BIOLOGICAL

RIV + rC19 (dose 2)

RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

BIOLOGICAL

RIV + rC19 (dose 3)

RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

BIOLOGICAL

RIV + rC19 (dose 4)

RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

OTHER

Placebo (0.9% NaCl)

Normal saline

BIOLOGICAL

RIV (recombinant influenza vaccine)

Influenza, inactivated, split virus or surface antigen

BIOLOGICAL

rC19 (dose 1)

Protein subunit

BIOLOGICAL

RIV + rC19 (dose 1)

RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2026-04-03
Completion
2026-04-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06695130 on ClinicalTrials.gov